← Oncology Approval Tracker

FDA DECISION ·

Zynyz

retifanlimab-dlwr · Incyte

FDA approvalNew or expanded indicationAnal canal squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

With carboplatin and paclitaxel as first-line therapy for adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

LAMPGEN ANALYSIS

Why it matters

POD1UM-303 established a first-line combination of a PD-1 inhibitor and platinum-taxane chemotherapy in this rare cancer.

What research teams should watch

Track induction cycles and the transition from combination therapy to continued retifanlimab in the visit calendar.

PRIMARY RECORDS

Sources